In the last 10 years there has been increasing interest on the role of calcitonin gene-related peptide (CGRP) in primary headaches. Tension-type headache (muscle contraction headache) is one of the most common and important types of primary headaches and ongoing nociception from myofascial tissues may play an important role in the pathophysiology of this disorder. CGRP sensory fibers are preferentially located in the wall of arteries and nerve fibers containing CGRP accompany small blood vessels in human cranial muscles. It is well established that nociception may lead to release of CGRP from sensory nerve endings and from central terminals of sensory afferents into spinal cord. It has also been shown that density of CGRP fibers around arteries is increased in persistently inflamed muscle. These findings indicate that ongoing activity in sensory neurons in the cranial muscles may be reflected in changes of plasma levels of neuropeptides in patients with tension-type headache. To explore possible role of CGRP in tension-type headache, plasma levels of CGRP were measured in patients with chronic tension-type headache. This study showed that plasma levels of CGRP are normal in patients and largely unrelated to headache state. Findings of normal plasma CGRP add to the growing list of differences between migraine and tension-type headache. However, the findings of normal plasma levels of CGRP do not exclude that abnormalities of this neuropeptide at the neuronal or peripheral (pericranial muscles) levels play a role for the pathophysiology of tension-type headache. Investigation of CGRP in other compartments with new sensitive methods of analysis is necessary to clarify its role in tensiontype headache.
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